Abstracts tagged "MicroRNA"

Abstract Number: 1613 • 2014 ACR/ARHP Annual Meeting
Circulating microRNAs As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus
Juyang Jung¹, Ja-Young Jeon², Bong-Sik Kim³, Hyoun-Ah Kim² and Chang-Hee Suh⁴, ¹Ajou university of medical school, Suwon, South Korea, ²Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ³Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁴Rheumatology, Ajou University School of Med, Suwon, South Korea
Background/Purpose : Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by polyclonal B-cell activation and elevated production of pathogenic autoantibodies. MicroRNAs (miRNAs) are short,…
Abstract Number: 1202 • 2014 ACR/ARHP Annual Meeting
Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE
Bo Qu¹, Jianchang Cao², Feifei Zhang² and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Systemic lupus erythematosus (SLE) is characterized by the uncontrolled inflammation along with over produced inflammatory cytokines, among which type I interferon (IFN) is recognized…
Abstract Number: 2 • 2013 ACR/ARHP Annual Meeting
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Raul Teruel², Ángeles Aguirre Zamorano¹, Rosario M. Carretero-Prieto¹, Nuria Barbarroja¹, Antonio Rodriguez-Ariza³, Eduardo Collantes-Estevez⁴, Rocio gonzalez-Conejero², Constantino Martinez², Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: miRNAs are key players in pathophysiological processes, but no previous studies have investigated their asscociation with the cardiovascular and atherothrombotic risks observed in primary…
Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting
Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Patrícia Costa-Reis¹, Pierre Russo² and Kathleen E. Sullivan³, ¹Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…
Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 2698 • 2013 ACR/ARHP Annual Meeting
The Treg/Th17 Imbalance Of Patients With Systemic Lupus Erythematosus Were Mediated By Mir-663 Through Down-Regulating TGF-β1 Secretion Of Bone Marrow-Derived Mesenchymal Stem Cells
Lingyu Geng¹, Xia Li¹, Xuebing Feng² and Lingyun Sun³, ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) patients exist an imbalance between CD4+CD25+FoxP3+ T regulatory (Treg) and IL-17-producing cells (Th17). Correction of this Treg/Th17 imbalance may have…
Abstract Number: 2559 • 2013 ACR/ARHP Annual Meeting
Effect Of NOX4 Overexpression On The Levels Of Micro RNAs Relevant To Systemic Sclerosis Fibrotic Process
Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is characterized by the excessive deposition of collagen and other connective tissue components in skin and multiple internal organs. Although transforming…
Abstract Number: 2423 • 2013 ACR/ARHP Annual Meeting
Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte
Marina Frleta¹, Ashleigh-Ann Rainey², Derek S. Gilchrist³, Lynn Crawford³, Derek Baxter³, Mariola Kurowska-Stolarska⁴ and Iain B. McInnes², ¹Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Whereas molecular mechanisms mediating treatment responses to biologic DMARDS in Rheumatoid Arthritis (RA) are emerging, those pathways that subserve treatment resistance are poorly explored.…
Abstract Number: 1622 • 2013 ACR/ARHP Annual Meeting
Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis
Beatrice Goilav¹, Iddo Z. Ben-Dov², Irene Blanco³, Olivier Loudig⁴, Dawn M. Wahezi⁵ and Chaim Putterman⁶, ¹Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ²Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Epidemiology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN), particularly, ISN/RPS class IV LN, is associated with significant morbidity and mortality. microRNAs (miRs) are small, non-coding RNAs that regulate translation.…
Abstract Number: 1161 • 2013 ACR/ARHP Annual Meeting
Microrna-155 As a Proinflammatory Regulator via SHIP-1 Down-Regulation In Acute Gouty Arthritis
Hye Mi Jin¹, Young-Nan Cho¹, Seung-Jung Kee², Dong-Jin Park³, Yong-Wook Park³, Shin-Seok Lee⁴ and Tae-Jong Kim¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Gout is characterised by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory…
Abstract Number: 941 • 2013 ACR/ARHP Annual Meeting
Mir-34a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance
Clare E Tange¹, Stefano Alivernini², Derek S. Gilchrist³, Lynn Crawford³, Ashleigh-Ann Rainey¹, Derek Baxter³, Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Cells of the monocyte/macrophage lineage are critical to RA pathogenesis: unravelling mechanisms underlying macrophage inflammatory gene expression should elucidate novel disease-associated pathways and thereby…
Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Ashleigh-Ann Rainey¹, Derek S. Gilchrist², Clare E Tange¹, Marina Frleta³, Lynn Crawford², Derek Baxter², Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…
Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Sophine B. Krintel¹, Christian Dehlendorff², Merete Lund Hetland³, Kim Hørslev-Petersen⁴, Klaus K. Andersen², Peter Junker⁵, Jan Pødenphant⁶, Torkell Ellingsen⁷, Palle Ahlqvist⁸, Hanne M. Lindegaard⁹, Asta Linauskas¹⁰, Annette Schlemmer¹¹, Mette Y. Dam¹², Ib Hansen¹³, Hans Chr Horn¹⁴, Anette Jørgensen¹⁵, Johnny Raun¹⁶, Christian G. Ammitzbøll¹², Mikkel Østergaard¹⁷, Kristian Stengaard-Pedersen¹² and Julia S. Johansen¹⁸, ¹Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁵University of Southern Denmark, Odense, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Silkeborg Regional Hospital, Silkeborg, Denmark, ⁸University of Southern Denmark, Vejle, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Vendsyssel Hospital, Hjørring, Denmark, ¹¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹²Arhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁴Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁵Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁶University of Southern Denmark, Graasten, Denmark, ¹⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ¹⁸Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].